Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia, Chronic Myelocytic Leukemia, Hodgkin's Disease, Myelodysplastic Syndrome
Conditions
Keywords
Allogeneic Bone Marrow Transplantation, Graft versus host disease, Tacrolimus, Sirolimus, Methotrexate, Pentostatin
Brief summary
The purpose of the study is to determine if participants who receive the GVHD prophylaxis medication pentostatin will have less severe hepatic toxicities than those receiving MTX. The study is estimated to have sufficient statistical power to ascertain at least a 20% improvement in day 42 NCI CTC grade 2 or above hepatic toxicity-free survival in pentostatin recipients.
Detailed description
Participants will be randomized to receive either methotrexate (MTX) or pentostatin for graft-versus-host disease (GVHD) prophylaxis after receiving an allogeneic bone marrow transplant from an HLA-matched related or unrelated donor. All participants will receive a standard backbone GVHD prophylaxis regimen (tacrolimus and sirolimus) and conditioning (cyclophosphamide/TBI). A risk-adapted approach will be used during conditioning to further minimize the risk of leukemia relapse based on two factors: 1. Lymphoid versus myeloid primary disease. 2. KIR compatibility between donor and host.
Interventions
DRUGMethotrexate
Participants will be randomized to receive either methotrexate (MTX) or pentostatin for graft-versus-host disease (GVHD) prophylaxis after receiving an allogeneic bone marrow transplant from an HLA-matched related or unrelated donor.
DRUGPentostatin
Participants will be randomized to receive either methotrexate (MTX) or pentostatin for graft-versus-host disease (GVHD) prophylaxis after receiving an allogeneic bone marrow transplant from an HLA-matched related or unrelated donor.
Sponsors
St. Jude Children's Research Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Months to 21 Years
Healthy volunteers
No
Inclusion criteria
\*Age less than or equal to 21 years old High risk malignancy as follows: * High-risk ALL in CR1. Examples include, but not limited to: Induction failure or \> 1% leukemic lymphoblasts in the bone marrow on remission date;\> 0.1% leukemic lymphoblasts in the bone marrow in week 7 of continuation treatment (i.e. before reinduction I); re-emergence of leukemic lymphoblasts by MRD (at any level) in patients previously MRD negative; persistently detectable MRD at lower levels;early T-cell precursor (ETP) ALL. * High-risk ALL beyond CR1, or with refractory disease. Beyond CR1 denotes any CR following CR1, or any relapsed state. Refractory disease includes induction failure. * High-risk de novo AML in CR1.Examples include but are not limited to:evidence of a high-risk genetic abnormality or high-risk MRD features. * AML beyond CR1, or with refractory disease. Beyond CR1 denotes any CR following CR1, or any relapsed state. Refractory disease includes induction failure. * Therapy-related AML. * MDS, primary or secondary, at any stage. * NK cell lymphoblastic leukemia in any CR * Biphenotypic bilineage, or undifferentiated leukemia. * CML in any phase * Hodgkin lymphoma beyond CR1 or with refractory disease. Beyond CR1 denotes any CR following CR1, or any relapsed state. * Non-Hodgkin lymphoma beyond CR1 or with refractory disease. Beyond CR1 denotes any CR following CR1, or any relapsed state. * Juvenile Myelomonocytic Leukemia (JMML). * All patients with prior evidence of CNS leukemia must be treated and be in CNS CR to be eligible for study. * Has a suitable HLA matched sibling or unrelated volunteer donor available for stem cell donation.A matched donor is defined as allele matching at 7/8 to 8/8 HLA loci at A, B, C and DRB1.For the purpose of this study, the term matched sibling also refers to an HLA matched family member. * Does not have any other active malignancy other than the one for which this transplant is indicated. * Left ventricular ejection fraction \> 40%,or shortening fraction \> 26%. * Forced vital capacity (FVC) greater than or equal to 50% of predicted value (corrected for hemoglobin), or if patient is unable to perform pulmonary function testing, pulse oximetry greater than or equal to 92% on room air. * Creatinine clearance greater than or equal to 70 ml/min/1.73m2 * Karnofsky or Lansky (age-dependent) performance score of greater than or equal to 70. * Bilirubin less than or equal to 2.5 mg/dL. * Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase less than or equal to 5 times upper limit of normal * Not pregnant as confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment. * Not lactating. * Has not had a prior allogeneic HSCT.
Exclusion criteria
* Pregnant and lactating females are excluded from participation as the short and long-term effects of the protocol interventions and infusion on a fetus or a nursing child through breast milk are not entirely known at this time.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Determining Whether the Hepatic Adverse Event-free (NCI Grades II-IV) Survival at Day 42 After an HLA-matched Transplant for Hematologic Malignancy Can be Improved by Using a GVHD Prophylaxis Regimen That Includes Pentostatin Rather Than MTX. | 42 days post-transplant | The hypothesis was that individuals receiving the drug pentostatin as GVHD prophylaxis would experience less severe hepatic toxicity than those receiving methotrexate as GVHD prophylaxis. The study is estimated to have sufficient statistical power to ascertain at least a 20% improvement in day 42 grade 2 or above hepatic toxicity-free survival in pentostatin recipients |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Assess Overall Survival, Relapse, Engraftment, and Regimen-related Morbidity and Estimating Cumulative Incidence of Pulmonary Adverse Events and Mucositis. | 42 days post- transplant | To characterize the pharmacokinetic-pharmacodynamic relationships of pentostatin in this patient population and to assess the relationship between pre-transplant minimal residual disease (MRD) and transplant outcomes. |
Countries
United States
Participant flow
Recruitment details
Six transplant patients were recruited between December, 2010 through March, 2011. Participants will be biologically stratified according to disease, donor, and KIR match.
Participants by arm
| Arm | Count |
|---|---|
| Methotrexate Participants will be biologically stratified according to disease, donor, and KIR match. In addition to a standard backbone of 2 GVHD prophylactics, a computer generated randomization procedure will assign participants to a third GVHD prophylactic medication (MTX or pentostatin)
Methotrexate: Participants were randomized to receive methotrexate (MTX) for graft-versus-host disease (GVHD) prophylaxis after receiving an allogeneic bone marrow transplant from an HLA-matched related or unrelated donor. | 2 |
| Pentostatin Participants will be biologically stratified according to disease, donor, and KIR match between donor and host. In addition to a standard backbone of 2 GVHD prophylactics, a computer generated randomization procedure will assign participants to a third GVHD prophylactic medication (MTX or pentostatin)
Pentostatin: Participants were randomized to receive pentostatin for graft-versus-host disease (GVHD) prophylaxis after receiving an allogeneic bone marrow transplant from an HLA-matched related or unrelated donor. | 4 |
| Total | 6 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Death | 0 | 1 |
| Overall Study | Protocol closure | 1 | 1 |
| Overall Study | Required additional transplant | 1 | 1 |
Baseline characteristics
| Characteristic | Methotrexate | Pentostatin | Total |
|---|---|---|---|
| Age Continuous | 10.35 years STANDARD_DEVIATION 0.07 | 12.95 years STANDARD_DEVIATION 6.65 | 12.08 years STANDARD_DEVIATION 5.32 |
| Sex: Female, Male Female | 1 Participants | 4 Participants | 5 Participants |
| Sex: Female, Male Male | 1 Participants | 0 Participants | 1 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 2 / 2 | 4 / 4 |
| serious Total, serious adverse events | 2 / 2 | 4 / 4 |
Outcome results
Primary
Determining Whether the Hepatic Adverse Event-free (NCI Grades II-IV) Survival at Day 42 After an HLA-matched Transplant for Hematologic Malignancy Can be Improved by Using a GVHD Prophylaxis Regimen That Includes Pentostatin Rather Than MTX.
The hypothesis was that individuals receiving the drug pentostatin as GVHD prophylaxis would experience less severe hepatic toxicity than those receiving methotrexate as GVHD prophylaxis. The study is estimated to have sufficient statistical power to ascertain at least a 20% improvement in day 42 grade 2 or above hepatic toxicity-free survival in pentostatin recipients
Time frame: 42 days post-transplant
Population: Insufficient data was available to answer objectives
Secondary
Assess Overall Survival, Relapse, Engraftment, and Regimen-related Morbidity and Estimating Cumulative Incidence of Pulmonary Adverse Events and Mucositis.
To characterize the pharmacokinetic-pharmacodynamic relationships of pentostatin in this patient population and to assess the relationship between pre-transplant minimal residual disease (MRD) and transplant outcomes.
Time frame: 42 days post- transplant
Population: Insufficient data was available to answer objectives.